September 26, 2017

Watch our webinar titled “How Changes to the Patented Medicine Prices Review Board Could Affect Patients’ Access to Drugs”

This webinar introduces you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients. This webinar...
Read More
September 22, 2017

New First Line Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer

KIRKLAND, QC, Sept. 20, 2017 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell...
Read More
September 21, 2017

First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza® (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement

This marks an important first step towards providing Canadian women with access to this treatment MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug...
Read More
September 14, 2017

Cancer-Associated Thrombosis: A Critical Gap in Cancer Care

"Cancer-associated thrombosis (CAT) is one of the most common yet preventable causes of death among cancer patients. With over 20,000 Canadians being diagnosed with cancer each year, knowing about causes,...
Read More
September 13, 2017

Registration Now Open for the Second Annual Drug Pricing Policy Summit

On November 15-16, 2017 from 8:30 a.m. - 5:00 p.m., you are invited to join the Save Your Skin Foundation, the Canadian Cancer Survivor Network and the Schizophrenia Society of...
Read More
September 11, 2017

Saskatchewan latest province to help protect boys from cancer with HPV vaccine

Grade 6 boys in Saskatchewan will now receive a vaccine to prevent some types of cancer. Starting this year 7,500 boys will be eligible to receive the human papillomavirus, or...
Read More
September 8, 2017

pCODR gives initial positive recommendation for Ovarian Cancer Drug

pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer. As part of their recommendation, pCODR stated that "Reimbursement should be for olaparib monotherapy...
Read More
September 5, 2017

Do You have Metastatic Prostate Cancer?

Bayer is conducting a research study in men with metastatic hormone-sensitive prostate cancer. The purpose of this study is to find out if the study drug is safe and effective...
Read More
August 31, 2017

Western Day 2017 Adapting to Survive: Innovation in Reimbursement in Western Canada

On Tuesday, September 12, 2017, the Canadian Association for Healthcare Reimbursement will host an event featuring some of the leaders in the Canadian Health industry. With a variety of panel...
Read More
August 28, 2017

2017 National Lymphedema Conference

Montreal • October 27-28 A bilingual conference co-hosted by the Canadian Lymphedema Framework and the Lymphedema Association of Québec in collaboration with the McGill University Health Centre and Concordia University....
Read More
1 35 36 37 38 39 67